NeuroSense Therapeutics Ltd., a foreign private issuer, has filed a report with the United States Securities and Exchange Commission (SEC) for the month of September 2024. The report, submitted on Form 6-K, indicates that NeuroSense Therapeutics has begun the process of complying with the Health Insurance Portability and Accountability Act (HIPAA) regulations. This initiative is part of the company's regulatory obligations in the United States. The filing, dated September 16, 2024, was signed by Alon Ben-Noon, an authorized representative of NeuroSense Therapeutics.

NeuroSense Therapeutics Ltd., a foreign private issuer, has filed a report with the United States Securities and Exchange Commission (SEC) for the month of September 2024. The report, submitted on Form 6-K, indicates that NeuroSense Therapeutics has begun the process of complying with the Health Insurance Portability and Accountability Act (HIPAA) regulations. This initiative is part of the company's regulatory obligations in the United States. The filing, dated September 16, 2024, was signed by Alon Ben-Noon, an authorized representative of NeuroSense Therapeutics.